When it comes to weight loss, more options mean greater opportunities to discover what works for you, and now there’s a significant new choice in the medication lineup: Zepbound.™
“Zepbound’s approval is a breakthrough in obesity treatment at a critical time,” said Rekha Kumar, MS, MD, an obesity medicine specialist and chief medical officer at Found Health. “The obesity epidemic is surging like never before, and U.S. life expectancy is at its lowest in decades, with obesity as a leading driver.”
Although medications like Ozempic® (semaglutide) and Mounjaro® (tirzepatide) can both be used for weight loss, those drugs are approved by the U.S. Food and Drug Administration (FDA) for type 2 diabetes. Only a few other medications—among them Wegovy,® which is also semaglutide-based, and Saxenda® (liraglutide)—have garnered FDA approval specifically for weight loss.
Fresh on the roster for FDA-approved weight loss medication is Zepbound. Developed by Eli Lilly, the same manufacturer that produces Mounjaro, this medication’s approval was based on results from multi-phase clinical trials. In that research, participants on the highest dose lost on average 48 pounds over 72 weeks—about half a pound per week—the kind of gradual progress that's crucial for long-term weight management. On the lowest dose, people taking Zepbound for weight loss lost on average 34 pounds.
According to Eli Lilly, Zepbound is expected to be available in the U.S. before the year’s end in different dose amount options. The big question many will ask is likely: How is Zepbound different from Wegovy?
The answer is that similar to the type 2 diabetes drug Mounjaro, Zepbound features a dual mechanism that contributes to weight loss. One has been shown to decrease food intake and increase energy expenditure, while the other helps regulate blood glucose levels and appetite, contributing to weight loss. Wegovy and Ozempic use a single mechanism mimicking a hormone called glucagon-like peptide-1. They promote weight loss by slowing digestion, causing people to feel fuller longer after eating and curbing appetite.
That doesn't mean one drug is better than the other. This just means you'll have more options to find a medication that's a good fit for you. To determine if Zepbound or another medication is right for your weight-loss journey, Found's doctor-designed weight-loss program leverages MetabolicPrint,™ a proprietary metabolic health assessment engine, and clinicians specializing in obesity medicine to find the right medication for you. We've gathered the information you'll need to know on Zepbound weight loss here.
A few important highlights you should know about Zepbound (tirzepatide) are:
The U.S.-based pharmaceutical company Eli Lilly manufactures Zepbound.
It is a once-weekly injectable medication.
The FDA approved the medication in early November.
Although Mounjaro’s active ingredient is also tirzepatide, it’s FDA-approved for treating type 2 diabetes (but can be prescribed off-label for weight loss); the FDA specifically approved Zepbound for weight loss as a treatment for obesity and overweight.
It is the first and only obesity treatment with a dual-targeted mechanism, relying on a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and glucagon-like peptide-1 (GLP-1) receptor agonist.
Why does this combination matter? In an April 2022 press release about tirzepatide—the active ingredient in Zepbound with the exact dual mechanism—Eli Lilly explained why these two mechanisms are so important. According to the release, the GIP hormone receptor agonist complements the GLP-1 hormone receptor agonist in a novel way: “GIP has been shown to decrease food intake and increase energy expenditure, resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids.” This means the two incretin hormone agonists work together to help maintain weight loss by regulating blood glucose levels and appetite, aiding body fat reduction.
But what are incretin hormones? After eating, your gut naturally releases incretin hormones—the two main ones are GIP and GLP-1. These hormones help regulate the insulin the pancreas releases to keep blood sugar levels under control effectively. More than that, the GLP-1 incretin hormone improves satiety and helps slow stomach emptying, causing you to feel fuller longer.
But those with excess weight or obesity can become insulin resistant—meaning their body doesn’t respond to the hormone’s signaling. This can result in too much glucose in the blood. Insulin resistance can lead to type 2 diabetes, weight gain, and elevated blood sugar levels.
"Unfortunately, despite scientific evidence to the contrary, obesity is often seen as a lifestyle choice—something that people should manage themselves," said Dr. Leonard Glass, senior vice president global medical affairs, Lilly Diabetes and Obesity, in the November 2023 announcement on Zepbound. "For decades, diet and exercise have been a go-to, but it's not uncommon for a person to have tried 20-30 times to lose weight with this approach. Research now shows that the body may respond to a calorie-deficit diet by increasing hunger and reducing feelings of fullness, making weight loss more difficult."
Using a medication like Zepbound for weight loss offers more options, particularly because it counteracts this inclination toward reduced fullness and increased hunger.
Eli Lilly noted that FDA approval was based on results from the phase 3 SURMOUNT-1 and SURMOUNT-2 trials. In SURMOUNT-1, a study in 2,539 adults with obesity, or excess weight and weight-related conditions (but not type 2 diabetes), people taking Zepbound as an adjunct to diet and exercise experienced substantial weight loss compared with placebo at 72 weeks. At the highest dose (15 mg), people taking Zepbound lost on average 48 pounds, while at the lowest dose (5 mg), people lost on average 34 pounds (compared to just 7 pounds on the placebo).
Additionally, 1 in 3 patients taking Zepbound at the highest dose lost over 58 pounds (25% of body weight), compared to 1.5% on placebo. The average starting weight was 231 pounds.
While Zepbound was not approved to treat cholesterol, high blood sugar or waist size, these health indicators improved in a clinical trial among people with weight-related medical conditions who dieted, exercised, and took Zepbound for weight loss, according to a November 2023 news release from Eli Lilly.
Fewer than one percent of medical providers have the right training to help you choose the proper medication for your weight loss journey. If you’re considering weight loss with Zepbound, GLP-1s, or any other medications for weight loss, consult an obesity-trained specialist first, such as those at Found Health. Remember to pair medication with lifestyle changes for sustainable weight loss.
Aside from your unique biology and medication needs, you'll want to consider a few factors before asking a provider about Zepbound.
According to Lilly’s list price, Zepbound costs $1,059.87 per four-week fill. The company notes the amount you pay will largely depend on your prescription drug insurance plan.
One option to consider is the Zepbound Savings Card Program from Eli Lilly. Although the manufacturer has yet to roll this out, the company notes the program will be available within days of product availability in U.S. pharmacies.
It’s worth noting that people across the U.S. have seen a decline in pharmaceutical coverage for GLP-1 receptor agonist medications in the last few months as insurers struggle to cover the demand for these drugs. One potential avenue for patients for whom Zepbound is the right medication is to indicate a history of using other medications for weight loss first. This practice is called step therapy, and your provider can walk you through it. At Found, providers have a portfolio of medications to prescribe to target each person’s needs for effective weight loss.
According to the Eli Lilly release on the medication, the most common side effects of Zepbound (tirzepatide) are:
Heartburn and belching
Injection site reactions
The company noted that in studies, most reactions like nausea, vomiting, and diarrhea occurred when people increased their dose—but the effects generally decreased over time.
Like GLP-1 receptor agonists, tirzepatide has an FDA-mandated boxed—or black box—warning for patients with a personal or family history of medullary thyroid cancer or who have multiple endocrine neoplasia syndrome type 2. They should not take tirzepatide for weight loss or any other treatment. Read more about tirzepatide here.
The Zepbound pen automatically injects the medication through its hidden needle. When you press the button on the Zepbound pen, the needle enters your skin and retracts when the injection is complete.
You use the Zepbound pen once weekly on a day that’s best for you. You can inject the medication into your upper arm, thigh, or abdominal area.
According to the FDA, after a starting dose of 2.5 mg a week over four weeks, the Zepbound dosage can be increased every four weeks to achieve the target dosages of 5 mg, 10 mg, or 15 mg weekly. The maximum dose of Zepbound is 15 mg weekly.
Today, there are other medications that are available as part of an obesity specialist’s toolkit when addressing each person’s unique biological needs.
Mounjaro, as mentioned, is a GIP/GLP-1 receptor agonist medication. There’s also an entire class of GLP-1 agonist drugs like Ozempic, Saxenda,® Trulicity,® Rybelsus,® Wegovy,®and Victoza.® There’s a lot of hype in the market today about these medications and their ability to help with weight management. As you can imagine, the demand has also created issues like supply shortages, insurance coverage gaps, and, at times, questionable prescribing practices.
All GLP-1 medications have the potential for minor and more serious side effects. Common side effects include nausea, vomiting, diarrhea, and acid reflux. More serious but less common side effects include pancreatitis, gallbladder disease, and worsening diabetic eye disease. You should not use these drugs if you have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasias. Detailed side effects and risk information for specific GLP-1 medications can be found here.
Alternatively, there are other weight loss drugs providers can prescribe that are more cost-effective and typically don’t require step therapy. These medications also don’t involve weekly injections. And they’re often the first line of drugs used to treat excess weight and obesity.
Gaining FDA approval for weight loss is a significant step forward, not just for Zepbound but also for those who want more options when it comes to a weight loss treatment plan.
When you’re ready, a Found-affiliated obesity-trained health care provider will be able to determine if Zepbound weight loss is right for you. Found is among the largest medically-supported telehealth weight care clinics in the country, having served more than 200,000 members to date. To discover your MetabolicPrint and start your journey with Found, take our quiz.
GLP-1 prescriptions, filled through your local pharmacy, are now available as part of Found's weight-loss toolkit. While GLP-1s are effective for weight loss, they are not clinically appropriate for everyone. Eligibility for a GLP-1 is based on a thorough evaluation of your medical history, eating behavior, lab work, and insurance coverage. If a GLP-1 is not appropriate for you, our providers will work with you to determine an effective medication for your health profile.